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Abstract
Denosumab is the international name of a human, monoclonal antibody approved for the treatment of osteoporosis. This antibody is
associated with RANK ligand (RANKL), inactivating it. In consequence, the formation and survival of osteoclasts are suppressed, leading
to their apoptosis. All this results in lower bone resorption, while bone mineral density (BMD) increases.
Denosumab also reduces the risk of vertebral and non-vertebral fractures. This agent is similarly effective in various stages of renal func-
tion impairment; it does not impair fracture healing processes nor contribute to atherosclerosis progression in patients with high cardio-
vascular risks. Following an analysis of adverse effects, performed in the FREEDOM study (in which it was demonstrated that the inci-
dence of the majority of adverse effects observed in the course of denosumab use was similar to that in the placebo group), its safety for
patients can definitely be confirmed. (Pol J Endocrinol 2011; 62 (1): 79–83)
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Streszczenie
Denosumab to nazwa międzynarodowa ludzkiego, monoklonalnego przeciwciała, dopuszczonego do leczenia osteoporozy. Przeciwciało
to wiąże się z ligandem RANK (RANKL), unieczynniając go. Na skutek tego dochodzi do zahamowania tworzenia się i przeżycia osteokla-
stów i do ich apoptozy. W wyniku tego zmniejsza się resorpcja kości, a co za tym idzie, zwiększa się ich gęstość mineralna (BMD, bone
mineral density). Denosumab zmniejsza też ryzyko złamań kręgosłupa i złamań pozakręgowych. Lek ten jest podobnie skuteczny w róż-
nych stadiach upośledzenia czynności nerek, nie upośledza gojenia się złamań i nie powoduje progresji miażdżycy u chorych wysokiego
ryzyka sercowo-naczyniowego. Na podstawie analizy działań niepożądanych przeprowadzonych w badaniu FREEDOM (w którym wy-
kazano, że częstość olbrzymiej większości występujących w trakcie jego stosowania objawów niepożądanych jest podobna jak w grupie
placebo) można stwierdzić, że lek ten jest bezpieczny dla chorych. (Endokrynol Pol 2011; 62 (1): 79–83)
Słowa kluczowe: denosumab, RANK, RANKL, złamania
Introduction
Receptor-activator of nuclear factor kB, known as
RANK, is the key factor stimulating the maturation,
proliferation and fusion of preosteoclasts, as well as
supporting the osteoclastic activity of mature osteoclasts
and maintaining their survival. The RANK receptor is
similar to the other receptors belonging to the so-called
TNF receptor family, at least regarding the extracellu-
lar domain, the structure of which resembles that of the
CD40 particle. However, the intracellular domain is not
like any known receptors belonging to the TNF family.
Activation of the RANK receptor leads to activating
intracellular signals, leading to the activation of vari-
ous transcriptive factors, which, in turn, influence the
expression of such genes as the calcitonin receptor gene,
TRAP, CATK, integrin b, INF, NFAT2, myc, src and oth-
ers. Their activation results in the stimulation of matu-
ration and activities of osteoclasts, which, in effect, leads
to bone mass loss, osteoporosis development and the
occurrence of fractures [1, 2]. Osteoprotegerin (OPG,
a bone-protecting substance), which can bind a RANKL
particle, protects the system against these effects in
physiological conditions, which makes the ligand-re-
ceptor binding impossible. OPG exerts a RANKL-op-
posing activity, thus protecting against osteoporosis.
The RANK/RANKL/OPG system also participates in
the pathogenesis of many other diseases of the osteoar-
ticular system, as set out in Table 1. The system seem-
ingly plays a certain role in the pathogenesis of athero-
sclerosis. For example, mice with congenital deficits of
osteoprotegerin develop vascular calcifications [4] and
any interference in the RANK/RANKL/OPG system may
reduce calcium deposition in the coronary vessels [5].
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So it is possible that osteoporosis and atherosclerosis,
two very often comorbid diseases, may have a common
pathogenetic basis [6].
As should be clear from the above statements, a phar-
macological suppression of the RANK/RANKL/OPG
system could reduce bone resorption.
Great expectations have been associated with such
a treatment, namely that it may also decrease the inci-
dence of fractures in patients with osteoporosis. The first
attempts at such therapy were undertaken with the use
of recombined osteoprotegerin, although this has yet
to enter the stage of advanced clinical trials. It has now
been replaced by an anitibody against RANKL.
This antibody has been launched onto the market
under the international name of denosumab. It is
a monoclonal, entirely human antibody of IgG2 type.
Available literature data regarding its efficacy and safe-
ty is discussed below (Table I).
Denosumab’s effects on fracture risk
reduction
Fracture risk reduction is the most important end-point
in all studies of medical agents used in the treatment of
osteoporosis and the ultimate goal of anti-osteoporotic
therapy.
The anti-fracture effect of denosumab was evaluat-
ed in the FREEDOM study, a randomised, double-blind,
placebo-controlled clinical trial [14]. A total of 7,868
women were enrolled into the study, their ages vary-
ing between 60 and 90 years and their bone mineral
density (BMD), measured as T-score of the hip and/or
of the lumbar spine, within the range  –2.5 to –4.0 SD.
Vertebral fracture was diagnosed in 24% of the women
at therapy onset. Prior three-year treatment with oral
bisphosphonates (and, if its duration was shorter, at least
12 months were necessary from the last bisphospho-
nate administration to include such a patient), treatment
with i.v. bisphosphonates, PTH, strontium, calcitonin,
fluorides, glycocorticosteroids and other agents, which
could have affected BMD during the six weeks before
the start of our study, were the exclusion criteria. Vari-
ous diseases, which could in any way affect bone me-
tabolism, were also exclusion criteria. Calcium and vi-
tamin D were supplemented in all the patients through-
out the entire study duration.
After three years of the study, a significantly reduced
fracture risk was observed in the patients treated with
denosumab vs. the placebo group. The risk of fresh ver-
tebral fracture decreased during that period by 68% (p
< 0.001);during the first year the risk dropped by 61%,
during the second year by 78% and during the third
year by 68% (p < 0.001). During the three-year obser-
vation, the absolute fracture risk was 7.2% in the place-
bo-treated group as against only 2.3% in the denosum-
ab-treated group.
The risk of clinically overt fracture decreased by 69%,
and the risk of multiple fracture by 61%. In turn, the
risk of non-vertebral fracture fell by 20% (the absolute
risk was 6.5% in the denosumab-treated group and 8%
in the placebo-treated group, p = 0.01) and the risk of
hip fracture by 40% (p = 0.04). Kaplan-Meier curves
which show the end-points are presented in Figure 1.
Denosumab effects on BMD
and bone metabolism markers
These effects have been evaluated in several studies. In
one, 412 women were enrolled, all post-menopausal and
with low bone mineral density (BMD), measured by
T score of the lumbar spine between –1.8 and –4.5 or
T score of the femoral neck between –1.8 and –3.5. The
patients were randomised into denosumab-treated
groups, one with denosumab doses of 6, 14 or 30 mg
every three months, the other with denosumab doses
of 14, 60, 100 and 210 mg every six months, plus two
control groups, in which either alendronate or a place-
bo was administered [7]. After a year of denosumab
administration, a dose- and time-interval-dependent
increase of spinal (3–6.7%) and total hip (1.9–3.6%) BMD
was noted, together with a quick and reversible reduc-
tion of bone metabolism marker concentrations (e.g.
CTX concentration was reduced by almost 90%).
The study was then extended by a subsequent
12 months [8]. BMD increase was continued during the
second year, but its pace was slower. The total increase
Table I. Diseases, the pathogenesis of which involves
participation of the RANK/RANKL/OPG system
Tabela I. Choroby, w patogenezie których uczesticzy układ
RANK/RANKL/OPG
Metabolic diseases of bones
Paget’s disease:
— sporadic (increased RANKL expression, an increased
response of osteoclasts to RANK stimulation),
— familial (familial expansile osteolysis/familial Paget’s disease
— RANK activating mutation)
— juvenile (juvenile Paget’s disease
— OPG inactivating mutation)
Post-menopausal and secondary osteoporosis (e.g. in the course
of hyperparathyroidism, glucocorticoid-induced)
Neoplasms
Multiple myeloma
Osteolytic metastases
Neoplastic hypercalcemia
Rheumatoid arthritis
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Figure 1. Incidence of new vertebral, non-vertebral, and hip fractures. The primary end point was the incidence of new vertebral
fractures at 36 months (A, left), which is shown for each study year (A, right). Risk ratios (RRs) are for subjects in the denosumab-
receiving group, as compared with those receiving a placebo. Kaplan–Meier curves for the time period to the first non-vertebral fracture
(B) and the first hip fracture (C) were determined on the basis of the subjects who did not have any fracture or who did not leave the study
before the relevant time. The subjects at risk at 36 months included all those patients who completed the end-of-study visits at or after the
start of the window for the 36-month visit. Reprinted from [14], with permission
Rycina 1. Występowanie nowych złamań kręgów, pozakręgowych i złamań biodra. Pierwotny punkt końcowy, którym było wystąpienie
nowych złamań kręgów oceniano po 36 miesiącach leczenia, pokazano w części A (lewa strona), to samo po każdym roku leczenia (słupki
po prawej). Ryzyko względne (RR) oceniano dla chorych leczonych denosumabem, w porównaniu z tymi, którzy otrzymywali placebo.
Krzywe Kaplana-Meiera dotyczące czasu do wystąpienia pierwszego złamania pozakręgowego (B) i pierwszego złamania biodra (C)
oceniano w odniesieniu do osób, które nie miały żadnego złamania ani nie opuściły badania przed właściwym czasem. Liczba chorych
(No. at Risk) w 36 miesiącu dotyczący tych pacjentów, którzy odbyli wizytę końcową w lub po zakończeniu „okienka czasowego”
przewidywanego dla wizyty w 36. miesiącu. Przedrukowano za zgodą z: [14]
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(after 24 months) of spinal BMD vs. the pre-treatment
values was 4.13–8.89% (depending on the applied dose
of the drug). The suppression of bone metabolism mark-
ers was maintained throughout the study period.
The obtained results suggest that 60 mg of denos-
umab, administered every six months, was an optimal
therapeutic protocol. In that situation, the patients who
had completed the study (and agreed to its continua-
tion) were divided into groups [9]. In one, the treatment
with denosumab at a dose of 60 mg every six months
was continued; in a second group, the therapy was with-
drawn for 12 months, then recommenced; while in the
third group, the therapy was permanently terminated.
Patients who had originally received a placebo contin-
ued to do so, while the patients treated with alendr-
onate did not continue to receive that drug. Those treat-
ment protocols were continued for two years. The pa-
tients treated with denosumab demonstrated further
BMD increase (e.g. in lumbar spine by 9.4–11.8% vs. the
base values) and the concentrations of bone turnover
markers remained low during the entire study period.
Denosumab withdrawal decreased BMD values and
increased bone turnover marker concentrations, which,
however, returned to the values before therapy with-
drawal in the group of women in whom the treatment
was restarted [9].
Denosumab effects on BMD and bone turnover
markers were evaluated also in women with osteope-
nia. After two years of treatment with denosumab at
a dose of 60 mg every six months, spinal BMD increased
by 6.5% vs. the base values. A significant increase of
BMD was also observed in the hip, the radial bone and
the total body. Bone turnover marker concentrations
in serum demonstrated a significant drop, e.g. the mean
reduction of CTX concentration was almost 90% [10].
A comparison of the effects of denosumab
and alendronate on BMD and bone turnover
markers and an evaluation of sequential
administration of these two drugs
Apart from the above-mentioned phase II study, where
alendronate was administered in one of the control
groups, two other studies were performed evaluating
alendronate and denosumab.
In one, a 12-month therapy resulted in BMD in-
crease, higher by approximately 1% in patients treated
with denosumab vs. those treated with alendronate (spi-
nal BMD by 1.1%, hip BMD by 0.9% and radial bone
shaft BMD by 0.6%). The reduction of bone turnover
marker concentrations in serum was greater in the pa-
tients treated with denosumab [11].
In the other study, a sequential treatment was eval-
uated (a switch from alendronate to denosumab). Here
also, a significantly higher increase of BMD was ob-
served, with a simultaneously larger drop of bone turn-
over marker concentrations in the patients switched to
denosumab treatment vs. those who continued alendr-
onate administration [12].
In these studies comparing denosumab to alendr-
onate, the preferences of patients were also evaluated.
More than 60% of the patients prefer denosumab treat-
ment, with subcutaneous administration once every six
months, less than 20% prefer an alendronate tablet once
a week, and also less than 20% have no preferences at
all [13]. These results are not surprising in that they fol-
low the general tendency of patients towards medical
treatment with drugs which allow for longer intervals
between subsequent doses.
Additional analyses of data
from the FREEDOM study
To date, a few additional analyses have been performed
of data from the FREEDOM study; thus far, the data
has been published as conference abstracts, briefly dis-
cussed below:
Denosumab in patients at high fracture risk
In an analysis comparing various subpopulations at high
fracture risk with other patients (e.g. women aged over
75, women with vertebral fractures present at the time
of randomisation vs. women without such fractures, as
well as women with a few concomitant fracture risk fac-
tors vs. other patients), it was demonstrated that, in the
majority of those subpopulations, denosumab was ef-
fective, both in the patients at lower, and those at high-
er, fracture risk. The only exception was a similar effec-
tiveness of denosumab in reducing non-vertebral frac-
tures of women with a T score of the femoral neck higher
or lower than –2.5 [15].
Denosumab in patients with
impaired renal function
Denosumab’s effects have been evaluated regarding
BMD and risk reduction of fresh vertebral fractures,
depending on renal function, measured as the estimat-
ed glomerular filtration rate (eGFR) from creatinine con-
centration, following the Cockroft-Gault formula [16].
No significant differences were found in denosum-
ab activity in the groups of patients with eGFR > 90 ml/
/min, 60–89 ml/min, 30–59 ml/min and 15–29 ml/min.
It should, however, be mentioned that the small num-
ber of patients in the last group, i.e. patients with highly
impaired renal function, reduces the value of the ob-
tained result.
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Denosumab’s effects on the
development of vascular calcifications
An analysis evaluated aortal calcifications during the
study duration in 2,363 women at high cardiovascular
risk. Aortal calcification was assessed in a 24-degree
scale, according to lateral spinal images, taken in con-
formity with the FREEDOM study protocol. The results
of that analysis did not reveal any difference in the pro-
gression of aortal calcifications between the group of
patients treated with denosumab and the placebo group
[17]. So it seems that the drug does not increase athero-
sclerosis progression in such patients.
Denosumab and fracture healing
Also in that analysis, non-vertebral fracture healing com-
plications were evaluated and, in a small population
of patients with antebrachial fractures (distal part of
the radial bone), serial X-ray images were taken of the
fracture site. Neither any disturbances nor delays in frac-
ture healing were found in the group treated with
denosumab vs. the placebo group [18].
Adverse effects
The adverse effects of denosumab are best evaluated
on the basis of a FREEDOM study analysis, in which
their incidence rates were evaluated in the largest group
of patients, both after the medication and after a place-
bo. The effects occurred with similar prevalence in both
studied groups. In the patients treated with denosum-
ab, cutaneous changes and meteorisms were more fre-
quently observed, as well as hypodermitis, while falls
and cerebral concussions were seldom recorded. The
prevalence of other adverse effects did not significant-
ly differ in either group. Neither were any differences
observed in the prevalence of severe adverse effects,
the prevalence of symptoms leading to treatment with-
drawal, nor the prevalence of infections. It appears from
this analysis that denosumab is a medicinal product safe
for use by patients [19].
Summary
Denosumab is a safe and effective medicinal agent, ap-
proved for the treatment of osteoporosis [16].
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